Paula González-Alonso

6PUBLICATIONS
31CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.

Matthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera

|May 11, 2024
VRK1 Regulates Sensitivity to Oxidative Stress by Altering Histone Epigenetic Modifications and the Nuclear Phosphoproteome in Tumor Cells.

Elena Navarro-Carrasco, Eva Monte-Serrano, Aurora Campos-Díaz

|Jun 22, 2021
Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain.

Shirish Shukla, Weijiang Ying, Felicia Gray

|Sep 02, 2020
Covalent inhibition of NSD1 histone methyltransferase.

Huang Huang, Christina A Howard, Sergei Zari

|May 15, 2020
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.

Sandra Zazo, Paula González-Alonso, Ester Martín-Aparicio

|May 06, 2020
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.

Paula González-Alonso, Sandra Zazo, Ester Martín-Aparicio

Pageof 1